Blueprint Medicines Management
Management criteria checks 3/4
Blueprint Medicines' CEO is Kate Haviland, appointed in Apr 2022, has a tenure of 1.92 years. total yearly compensation is $6.22M, comprised of 11.3% salary and 88.7% bonuses, including company stock and options. directly owns 0.098% of the company’s shares, worth $5.68M. The average tenure of the management team and the board of directors is 3.5 years and 8.9 years respectively.
Key information
Kate Haviland
Chief executive officer
US$6.2m
Total compensation
CEO salary percentage | 11.3% |
CEO tenure | 1.9yrs |
CEO ownership | 0.1% |
Management average tenure | 3.5yrs |
Board average tenure | 8.9yrs |
Recent management updates
Recent updates
Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Feb 20Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 08Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%
Dec 18Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Nov 07Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
Sep 15Blueprint to seek label expansion for systemic mastocytosis therapy after trial win
Aug 17Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance
Aug 02Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront
Jun 30Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook
Feb 17Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation
Nov 10Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)
Oct 15Blueprint Medicines: What Now
Jun 21CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$507m |
Sep 30 2023 | n/a | n/a | -US$555m |
Jun 30 2023 | n/a | n/a | -US$554m |
Mar 31 2023 | n/a | n/a | -US$581m |
Dec 31 2022 | US$6m | US$701k | -US$558m |
Sep 30 2022 | n/a | n/a | -US$718m |
Jun 30 2022 | n/a | n/a | -US$702m |
Mar 31 2022 | n/a | n/a | -US$650m |
Dec 31 2021 | US$4m | US$501k | -US$644m |
Sep 30 2021 | n/a | n/a | -US$411m |
Jun 30 2021 | n/a | n/a | US$340m |
Mar 31 2021 | n/a | n/a | US$325m |
Dec 31 2020 | US$2m | US$461k | US$314m |
Sep 30 2020 | n/a | n/a | US$333m |
Jun 30 2020 | n/a | n/a | -US$395m |
Mar 31 2020 | n/a | n/a | -US$371m |
Dec 31 2019 | US$3m | US$432k | -US$348m |
Sep 30 2019 | n/a | n/a | -US$362m |
Jun 30 2019 | n/a | n/a | -US$340m |
Mar 31 2019 | n/a | n/a | -US$267m |
Dec 31 2018 | US$3m | US$393k | -US$237m |
Sep 30 2018 | n/a | n/a | -US$205m |
Jun 30 2018 | n/a | n/a | -US$170m |
Mar 31 2018 | n/a | n/a | -US$177m |
Dec 31 2017 | US$1m | US$353k | -US$148m |
Compensation vs Market: Kate's total compensation ($USD6.22M) is about average for companies of similar size in the US market ($USD7.72M).
Compensation vs Earnings: Kate's compensation has increased whilst the company is unprofitable.
CEO
Kate Haviland (47 yo)
1.9yrs
Tenure
US$6,217,694
Compensation
Ms. Kathryn Haviland, also known as Kate, is Director of Bicara Therapeutic, Inc. from October 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serves as President, Chie...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.9yrs | US$6.22m | 0.098% $ 5.7m | |
Co-Founder & Director | no data | US$323.52k | 0.11% $ 6.6m | |
Chief Financial Officer | 8.1yrs | US$2.36m | 0.026% $ 1.5m | |
Chief Operating Officer | 1.9yrs | US$2.77m | 0.045% $ 2.6m | |
Executive VP | 7.5yrs | US$2.34m | 0.048% $ 2.8m | |
President of Research & Development | 3.5yrs | US$2.81m | 0.045% $ 2.6m | |
Senior VP | 1.2yrs | no data | 0.024% $ 1.4m | |
Senior VP of Technical Operations and Chief Technical Operations & Quality Officer | 6.4yrs | US$3.79m | 0.055% $ 3.2m | |
Chief Scientific Officer | 2.8yrs | US$4.59m | 0.079% $ 4.6m | |
Senior Director & Head of Investor Relations | no data | no data | no data | |
Chief People Officer | 4.1yrs | no data | 0.043% $ 2.5m | |
Senior Vice President of Corporate Affairs | no data | no data | no data |
3.5yrs
Average Tenure
52yo
Average Age
Experienced Management: BPMC's management team is considered experienced (3.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.9yrs | US$6.22m | 0.098% $ 5.7m | |
Co-Founder & Director | 12.9yrs | US$323.52k | 0.11% $ 6.6m | |
Member of Scientific Advisory Board | 11.8yrs | US$333.38k | no data | |
Lead Independent Director | 7.9yrs | US$373.59k | 0.014% $ 797.5k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board & Independent Director | 12.9yrs | US$348.45k | 0.087% $ 5.0m | |
Independent Director | 8.1yrs | US$346.39k | 0.014% $ 797.5k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 2.3yrs | US$326.51k | 0.0061% $ 354.1k | |
Chairman | 9.7yrs | US$1.59m | 0.24% $ 14.1m |
8.9yrs
Average Tenure
61yo
Average Age
Experienced Board: BPMC's board of directors are considered experienced (8.9 years average tenure).